acute myeloid leukemia
Conditions
Interventions
HCV:Venetoclax+azacitidine/decitabine+cladribine
Sponsors
Children's Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Age< 18 years old, Male and female unlimited; 2. AML patients diagnosed according to the 2016 World Health Organization (WHO) diagnostic criteria for myeloid malignancies (except M3 with positive PML/RARA) ; 3. Patients who have had at least one previous systemic therapy (including chemotherapy, Hematopoietic stem cell, etc.) without remission or relapse after remission; 4. ECOG score was 0-3; 5. Expected Survival Time =3 months; 6. No serious heart, lung, liver, Kidney Disease; 7. The patient or his or her parents understand and are willing to sign this informed consent form.
Exclusion criteria
Exclusion criteria: 1. Previously allergic to a drug included in a test protocol or to a drug with a similar chemical structure to the drug being tested; 2. Down syndrome associated with AML3; 3. Mental illness or other conditions, for which informed consent is not available; 4. Abnormal liver function (TBL> 3 times the upper limit of normal value, ALT/AST> 10 times the upper limit of normal value) ; 5. Abnormal renal function (Serum Creatinine> 3 times the upper limit of normal value) ; 5. The researchers determined that it was not suitable for the participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission;complete remission with incomplete bloodcount recovery;partial remission;Minimal residual disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| event-free-survival;relapse-free survival;overall survival;Volume of blood transfusion;time of Hematological recovery;Infection rate; | — |
Countries
China
Contacts
Public ContactHu Shaoyan
Outcome results
None listed